BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers. 

BiPar Sciences' lead product candidate, BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation.  By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.

BiPar Sciences has completed enrollment for a Phase 2 clinical study of BSI-201 in patients with triple negative metastatic breast cancer and will be initiating a Phase 3 study for this patient population in Summer 2009. BSI-201 is also being evaluated in multiple Phase 2 studies in other malignancies. The company also has two additional compounds in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy.